FormA Tobevalid,thewholeofthisdocumentmustbereturned. 表格甲 本文件必须整份交 还，方 为有 效。 IMPORTANT 重要提示 Reference is made to the prospectus issued by New Ray Medicine International Holding Limited (“Company”)dated10February2017inrelationtotheRightsIssue(“Prospectus”).Termsdefinedinthe Prospectusshallhavethesamemeaningswhenusedhereinunlessthecontextotherwiserequires. 兹提述新锐医药国际控股有限公 司（「本公 司」）日 期为二零一七年二月十日就供股刊发之章 程（「章程」）。除文 义另有所指外，章程所界定之词汇与本文件所采用者具有相同涵义。 THISPROVISIONAL ALLOTMENTLETTER(“PAL”)IS VALUABLEAND TRANSFERABLEAND REQUIRES YOURIMMEDIATEATTENTION.THEOFFERCONTAINEDINTHISPALANDTHEACCOMPANYINGEXCESS APPLICATION FORM(“EAF”)EXPIRESAT4:00 P.M.ONFRIDAY, 24FEBRUARY2017(OR,UNDERBAD WEATHERCONDITIONS,SUCH LATERTIMEORDATE ASMENTIONEDIN THEPARAGRAPH HEADED “EFFECTOFBADWEATHER”OVERLEAF). 此乃有价值及可转让的暂定配额通知书（「暂定配额通知书」），并须 阁下即时处理。本暂定配额通知书及随附 的额外申请表格（「额 外申请表格」）所 载的要约将於二零一七年二月二十四 日（星期五 ）下 午四时正（或於恶劣 天气情况 下，则 於背 页「恶劣天气的影响」一 段所述之有关较後时间或日期）届满。 IFYOUAREINANYDOUBTASTOANYASPECTOFTHISPAL,ORASTOTHEACTIONTOBETAKEN, ORIFYOUHAVESOLDORTRANSFERREDALLORPARTOFYOURSHARES,YOUSHOULDCONSULT YOURLICENSEDSECURITIESDEALERORREGISTEREDINSTITUTIONINSECURITIES,BANKMANAGER, SOLICITOR,PROFESSIONALACCOUNTANTOROTHERPROFESSIONALADVISER. 阁下如对本暂定配额通知书任何方面或应采取之行动有任何疑问或阁下如已出售或转让阁下全部或部分股 份，应谘询 阁下的持牌证券交易商或注册证券机 构、银 行经 理、律师、专业会计师或其他专业顾 问。 A copyofeachoftheProspectus Documents,togetherwith thedocuments specifiedintheparagraph headed“14.DocumentsdeliveredtotheRegistrarofCompanies”inAppendixIIItotheProspectus,has beenregisteredbytheRegistrarofCompaniesinHongKongpursuanttoSection342CoftheCompanies (WUMP)Ordinance(Chapter32oftheLawsofHongKong).TheRegistrarofCompaniesinHongKong,the StockExchangeandtheSecuritiesandFuturesCommissionofHongKongtakenoresponsibilityforthe contentsofanyofthesedocuments. 各份章程文件连同章程附录三内「14.送呈公司注册处处长之文件」一段所述之文件，已根据香港法例第32章公 司（清盘及杂项条 文 ）条 例 第342C条 之规定送呈香港公司注册处处长登记。香港公司注册处处长、联交所及香港 证券及期货事务监察委员会对任何该等文件之内容概不负 责。 HongKongExchangesandClearingLimited,theStockExchangeandHKSCCtakenoresponsibilityforthe contentsofthisPAL,makenorepresentationastoitsaccuracyorcompletenessandexpresslydisclaim anyliabilitywhatsoeverforanylosshowsoeverarisingfromorinrelianceuponthewholeoranypartofthe contentsofthisPAL. 香港交易及结算所有限公司、联 交所及香港结算对本暂定配额通知书之内容概不负 责，对其准确性或完整性亦 不发表任何声明，并 明确表示概不就因本暂定配额通知书全部或任何部分内容而产生或因倚赖该等内容而引致 之任何损失承担任何责任。 Subjecttothegrantingofthelistingof,andpermissiontodealin,theRightsSharesinboththeirnil-paid andfully-paidformsontheStockExchangeaswellascompliancewiththestockadmissionrequirements of HKSCC, theRights Shares in both their nil-paid and fully-paid forms will be accepted aseligible securities by HKSCC for deposit,clearance and settlement in CCASS with effect from therespective commencementdatesofdealingsintheRightsSharesinboththeirnil-paidand fully-paidformsonthe StockExchangeorsuchotherdatesasmaybedeterminedbyHKSCC.Settlementoftransactionsbetween participantsoftheStockExchangeonanytradingdayisrequiredtotakeplaceinCCASSonthesecond tradingdaythereafter.AllactivitiesunderCCASSaresubjecttotheGeneralRulesofCCASSandCCASS OperationalProceduresineffectfromtimetotime. 待未缴股款及缴足股款供股股份获准於联交所上市及买卖後，并符合香港结算之证券收纳规定，未 缴股款及缴 足股款供股股份将获香港结算接纳为合资格证券，自 未缴股款及缴足股款供股股份各自於联交所开始买卖之日 期或於香港结算可能厘定之有关其他日期起，可於中央结算系统内寄存、结 算及交收。联交所参与者之间於任 何交易日之交易必须於其後第二个交易日於中央结算系统 交 收。於中央结算系统进行之所有活动均须依据不时 有效之中央结算系统一般规则及中央结算系统运作程序规则进 行。 NewRayMedicineInternationalHoldingLimited 新锐医药国际控股有限公司 (IncorporatedinBermudawithlimitedliability) （於百慕达注册成立之有限公司） (StockCode:6108) （股份代号：6108） RIGHTSISSUEOF1,249,344,000RIGHTSSHARESATHK$0.275PERRIGHTSSHARE ONTHEBASISOFTHREE(3)RIGHTSSHARESFOREVERYONE(1)SHAREINISSUE HELDONTHERECORDDATEPAYABLEINFULL ONACCEPTANCEBYNOTLATERTHAN4:00P.M.ONFRIDAY,24FEBRUARY2017 按於记录日期每持有一(1)股已发行股份获发三(3)股供股股份之 基准以每股供股股份0.275港元进行1,249,344,000股供股股份之供股 股款最迟须於二零一七年二月二十四日（星期五 ）下午四时正接纳时全数缴足 PROVISIONALALLOTMENTLETTER 暂定配额通知书 Branchshareregistrarand Registeredoffice: transferofficeinHongKong: 注册办事处： TricorInvestorServicesLimited ClarendonHouse Level22,HopewellCentre 2ChurchStreet 183Queen’sRoadEast HamiltonHM11 HongKong Bermuda 香港股份过户登记分处： Headquarters: B-C,37/F. 卓佳证券登记有限公司 DikaiInternationalCenter 香港 皇后大道东183号 19DanguiRoad 合和中心22楼 Hangzhou,thePRC Principalplaceofbusinessin HongKong: Room517,5thFloor TownHealthTechnologyCentre 10-12YuenShunCircuit SiuLekYuen,Shatin NewTerritories,HongKong 总 部： 中国杭州市 丹桂路19号 迪凯国际中心 37楼B-C室 香港主要营 业 地 点： 香港新界 沙田小沥源 源顺围10-12号 康健科技中心 5楼517室 10February2017 二零一七年二月十日 Name(s)andaddressofQualifyingShareholder(s) NumberofSharesregisteredinyourname(s) 合资格股东的姓名及地址 onThursday,9February2017 於二零一七年二月九日（星期四）登记於阁 下名下之股份数目 BoxA 甲栏 Number of Rights Shares provisionally allottedtoyousubjecttopaymentinfullon acceptancebynot laterthan 4:00p.m.on Friday,24February2017 暂定配发予 阁下之供股股份数目，股款须不 迟於二零一七年二月二十四日（ 星期五）下午 四时正前接纳时缴足 BoxB 乙栏 Totalsubscriptionmoniespayable 应缴认购股款总额 BoxC HK$ 丙栏港元 ProvisionalAllotment LetterNo. 暂定配额通知书编号 TOACCEPTTHISPROVISIONAL ALLOTMENTOFRIGHTSSHARESINFULL,YOUMUSTLODGETHIS PAL INTACTWITHTHEREGISTRAR,TRICORINVESTORSERVICESLIMITEDATLEVEL22, HOPEWELL CENTRE,183QUEEN’SROADEAST,HONGKONG,TOGETHERWITHAREMITTANCE INHONG KONG DOLLARS FOR THE FULL AMOUNT SHOWN IN BOX C ABOVE SO AS TO BE RECEIVED BY THE REGISTRARBYNOTLATERTHAN4:00P.M.ONFRIDAY,24FEBRUARY2017(OR,UNDERBADWEATHER CONDITIONS, SUCHLATER TIME ORDATE AS MENTIONEDIN THEPARAGRAPH HEADED “EFFECT OFBADWEATHER”OVERLEAF).ALLREMITTANCESMUSTBEMADEINHONGKONGDOLLARSAND CHEQUESMUSTBEDRAWNONANACCOUNTWITH,ORCASHIER’S ORDERSMUSTBEISSUEDBY, A LICENSEDBANKINHONG KONGANDMADEPAYABLETO“NEW RAYMEDICINEINTERNATIONAL HOLDING LIMITED－ PROVISIONAL ALLOTMENT” AND CROSSED “ACCOUNT PAYEE ONLY”. INSTRUCTIONSONTRANSFERANDSPLITTINGARESETOUTOVERLEAF.NORECEIPTWILLBEGIVEN FORSUCHREMITTANCE. TheRightsIssueisconditionaluponthefulfilmentoftheconditionssetoutundertheparagraphheaded “TheRightsIssue�CConditionsoftheRightsIssue”inthesectionheaded“LetterfromtheBoard”inthe Prospectus. TheUnderwritermayterminatetheUnderwritingAgreementbynoticeinwritingtotheCompanyatanytime priorto4:00p.m.onMonday,27February2017(i.e.theLatestTimeforTermination)if: (1) inthereasonableopinionoftheUnderwriter,thesuccessoftheRightsIssuewouldbemateriallyand adverselyaffectedby: (a) theintroductionofanynewregulationoranychangeinexistinglaworregulation(orthejudicial interpretationthereof)orotheroccurrenceofanynaturewhatsoeverwhichmayinthereasonable opinionoftheUnderwritermateriallyandadverselyaffectthebusinessorthefinancialortrading positionoftheGroupasawholeorismateriallyadverseinthecontextoftheRightsIssue;or (b) theoccurrenceof anylocal,national orinternational eventor change (whetheror notforming partofa seriesofeventsor changesoccurring,orcontinuingbefore,and/orafterthedateof theUnderwritingAgreement),ofapolitical,military,financial,economicorothernature(whether or not ejusdem generic with any of the forgoing),or in the natureof any local, national or internationaloutbreak orescalationofhostilitiesorarmedconflict,or affectinglocalsecurities marketswhichmay,inthereasonableopinionoftheUnderwriter,materiallyandadverselyaffect thebusinessorthefinancialortradingpositionoftheGroupasawhole;or (c) anymaterialadversechangeafterthesigningoftheUnderwritingAgreementinthebusinessorin thefinancialortradingpositionoftheGroupasawhole;or (d) theimpositionof any moratorium,suspension or materialrestriction ontradingin theShares generallyontheStockExchangeduetoexceptionalfinancialcircumstancesorotherwise;or (e) anysuspensioninthetradingofsecuritiesgenerallyortheSharesontheStockExchangefora periodofmorethan20consecutivebusinessdays,excludinganysuspensioninconnectionwith theclearanceoftheAnnouncementortheProspectus Documentsor otherannouncementsor circularsinconnectionwiththeRightsIssue;or (2) any materialadverse changein market conditions(including,withoutlimitation, a change infiscal ormonetarypolicyorforeign exchangeorcurrencymarkets,suspension orrestrictionoftradingin securitiesandachangeincurrencyconditionsincludesachangeinthesystemunderwhichthevalue oftheHongKongcurrencyispeggedwiththatofthecurrencyoftheUnitedStatesofAmerica)occurs whichinthereasonableopinionoftheUnderwritermakesitinexpedientorinadvisabletoproceedwith theRightsIssue;or (3) theProspectuscontainsinformation(eitherastotheconditionoftheGrouporastoitscompliance withanylawsortheListingRulesoranyapplicableregulations)whichhasnotpriortothedateof theUnderwritingAgreementbeenpubliclyannouncedorpublishedbytheCompanyandwhichmay inthereasonableopinionoftheUnderwriterismaterialtotheGroupasawholeandislikelytoaffect materiallyandadverselythesuccessoftheRightsIssueormightcauseaprudentinvestornottoapply foritsprovisionalallotmentofRightsSharesundertheRightsIssue. TheUnderwritershallbeentitledbynoticeinwritingtotheCompanyservedpriortotheLatestTimefor TerminationtorescindtheUnderwritingAgreementif,priortotheLatestTimeforTermination: (1) any material breach of any of the warranties or undertakings of the Company contained in the UnderwritingAgreementcomestotheknowledgeoftheUnderwriter;or (2) anyeventoccurringormatterarisingonorafterthedateoftheUnderwritingAgreementandpriorto theLatestTimeforTerminationwhichifithadoccurredorarisenbeforethedateoftheUnderwriting Agreementwouldhaverenderedanyoftherepresentations,warrantiesandundertakingsgivenbythe CompanycontainedintheUnderwritingAgreementuntrueorincorrectinanymaterialrespectcomes totheknowledgeoftheUnderwriter. In the event that the Underwriter exercises its rights to terminate or rescind the Underwriting Agreementasdescribedabove,theRightsIssuewillnotproceed. The Shareshave beendealt withonanex-rightsbasisfrom Wednesday,1February2017. Dealings in theRightsSharesintheirnil-paid formwilltakeplacefrom9:00a.m.onTuesday,14February2017to 4:00p.m.onTuesday,21February2017(bothdatesinclusive).IftheconditionsoftheRightsIssuearenot fulfilledortheUnderwritingAgreementisterminatedbytheUnderwriteratorbefore4:00p.m.onMonday, 27February2017(orsuchlatertimeastheUnderwritermayagreewiththeCompany),theRightsIssuewill notproceed. Accordingly,anypersonscontemplatingbuyingorsellingtheSharesuptothedatewhentheconditions of the Rights Issue are fulfilled (and the date onwhich the Underwriter’sright of termination of the UnderwritingAgreementceases),andanydealingsinthenil-paidRightsSharesfrom9:00a.m.onTuesday, 14February2017to4:00p.m.onTuesday,21February2017(bothdatesinclusive)shallbeartheriskthat theRights Issuemay not becomeunconditionalor may notproceed.AnyShareholderor otherperson contemplatinganydealingsintheSharesand/ornil-paidRightsSharesarerecommendedtoconsulttheir ownprofessionaladvisers. EachpersonacceptingtheprovisionalallotmentspecifiedinthisPALconfirmsthathe/she/ithasreadthe termsandconditionsandacceptanceproceduressetoutintheenclosedsheetandintheProspectusand agreestobeboundbythem. 阁下如欲接纳全部供股股份的暂定配额，必须将本暂定配额通知书整份连同以港元缴付之上文丙栏所示之全数 股款，於二零一七年二月二十四日（星期五）下午四时正前（或於恶劣天气情况下，则於背页「恶劣天气的影响」 一段所述之有关较後时间或日期 ）交 回 登 记 处卓佳证券登记有限公司（地址为香港皇后大道东183号合和中心22 楼）并获登记处收讫。所有股款须以港元缴付，并 以在香港持牌银行户口开出的支票或以香港持牌银行发出的 银行本票支付。所有支票或银行本票均须注明抬头人为「NEWRAYMEDICINEINTERNATIONALHOLDING LIMITED－PROVISIONALALLOTMENT」，并 以「只准入抬头人账 户」划线方式开 出。有关转让及分拆配额 的指示载於背页。本 公司将不就有关股款另发收据。 供股须待章程「董事会函 件」一节「供股一供股之条件」一段所载条件达成後，方 可作 实。 倘出现下述情况，包 销商可於二零一七年二月二十七日（星期一）下午四时正（即最後终止时限 ）前随时向本公 司发出书面通知以终止包销协 议： (1) 包销商合理认为供股之成功将因以下各项而受到重大不利影响： (a)引入任何新法规或任何现有法例或法规（或其司法诠释）之变动，或发生属任何性质之其他事件，而 包销商可能合理认为对本集团之整体业务或财务或经营状况造成重大不利影 响，或对供股而言属重 大不利；或 (b)发生政治、军 事、财 务、经济或其他性质（不论是否与前述任何一项同类）之任何本地、国 家或国际事 件或变 动（不论是否构成於包销协议日期之前及�u或之後发生或持续之连串事件或变动之一部分 ）， 或性质为任何本地、国 家或国际骚动或敌对行为或武装冲突之 升 级，或 影 响本地证券市场之事件或变 动，而包销商可能合理认为对本集团之整体业务或财务或经营状况造成重大不利影响；或 (c) 於签订包销协议後，本 集团之整体业务或财务或经营状况有任何重大不利变 动；或 (d) 股份在联交所之买卖因特殊金融情况或其他原因而被全面禁 止、暂停或施加重大限制；或 (e) 联交所全面暂停证券买卖或暂停股份买卖，为期超过连续20个营业日（因审批公告或章程文件或与供 股有关之其他公告或通函而暂停者除外 ）；或 (2) 市况出现任何重大不利 变 动（包括但不限於财政或货币政策或外汇或货币市场变 动，或证券买卖被暂停或 受到限制以及货币状况变动，包 括香港货币与美利坚合众国货币汇价挂�h体系之变动 ），而包销商合理认 为将导致进行供股为不宜或不智；或 (3) 章程载有於包销协议日期前并未由本公司宣布或刊发之资料（不论有关本集团之状况或有关本集团遵守任 何法例或上市规则或任何适用法规 ），而 包销商可能合理认为对本集团整体而言乃属重 大，并 可能会对供 股之成功造成重大不利影响，或 导致审慎投资者不申请认购其於供股项下之供股股份暂定配额。 倘於最後终止时限前发生以下事 项，包销商将有权於最後终止时限前向本公司发出书面通知以撤回包销协议： (1) 包销商获悉本公司严重违反任何载於包销协议之保证或承 诺；或 (2) 包销商获悉於包销协议日期或之後但於最後终止时限前出现或发生任何事件或事项，而倘有关事件或事项 於包销协议日期前出现或发 生，将会导致本公司於包销协议项下作出之任何声明、保 证及承诺於任何重大 方面变为失实或不准确。 倘包销商行使其上述权利终止或撤回包销协议，则 供股将不会进行。 股份已於二零一七年二月一日（星期 三 ）起 按除权基准买卖。未缴股款供股股份将於二零一七年二月十四日（星 期二）上午九时正起至二零一七年二月二十一日（星期二 ）下 午四时正（包括首尾两日）买卖。倘於二零一七年 二月二十七日（星期一）下午四时正（或包销商与本公司可能协定之有关较後时间 ）或 之前，供股条件并未达成 或包销协议被包销商终止，则 供股将不会进行。 因此，有意於供股条件达成当日（及包销商终止包销协议之权利停止当 日 ）前 买 卖 股份及由二零一七年二月十四 日（星期二 ）上午九时正起至二零一七年二月二十一日（星期二 ）下午四时正（包括首尾两日）买卖任何未缴股 款供股股份之任何人士，均须承担供股可能不会成为无条件或可能不会进行之风险。拟 买卖任何股份及�u或未 缴股款供股股份之任何股东或其他人士应谘询彼等本身之专业顾问。 接纳本暂定配额通知书所载之暂定配额的每位人士均确认其已阅读所附文件及章程所载之条款及条件以及接 纳手 续，并同意受其约束。 ASEPARATECHEQUEORCASHIER’SORDERMUSTACCOMPANYEACHAPPLICATION NORECEIPTWILLBEGIVENFORREMITTANCE 每份申请须随附一张独立开出的支票或银行本票 本公司将不就股款另发收据 �CThispageisintentionallyblankpage�C －此乃白页－ INTHEEVENTOFTRANSFEROFRIGHT(S)TOSUBSCRIBEFOR RIGHTSSHARE(S),ADVALOREM STAMP DUTY IS PAYABLE ON EACH SALE ANDEACH PURCHASE. A GIFT OR TRANSFEROF BENEFICIALINTERESTOTHERTHANBYWAYOFSALEISALSOLIABLETOADVALOREMSTAMP DUTY. EVIDENCE OF PAYMENT OF AD VALOREM STAMP DUTY WILL BE REQUIRED BEFORE REGISTRATIONOFANYTRANSFEROFTHERIGHT(S)TOSUBSCRIBEFOR THERIGHTSSHARE(S) REPRESENTEDBYTHISDOCUMENT. 如转让供股股份的认购权，每项买卖均须缴付从价印花税。除以出售形式外，馈赠或转让实益拥有的权益亦须 缴付从价印花税。 在登记转让本文件所代表之认购供股股份之权利前，须出示已缴付从价印花税的证 明。 FORMOFTRANSFERANDNOMINATION 转让及提名表格 FormB (TobecompletedandsignedonlybyQualifyingShareholder(s)whowish(es)totransferall 表格乙 ofhis/her/its/theirright(s)tosubscribefortheRightsShare(s)comprisedherein) （只供拟转让其�u彼等全部供股股份认购权的合资格股东填写及签署） To: TheDirectors NewRayMedicineInternationalHoldingLimited 致： 新锐医药国际控股有限公司 列位董事 台照 DearSir/Madam, I/Weherebytransferallofmy/ourrightstosubscribefortheRightsSharescomprisedinthisPALtothe person(s)acceptingthesameandsigningtheregistrationapplicationform(FormC)below. 敬启 者： 本人�u吾等谨将本暂定配额通知书所列本人�u吾等的供股股份的认购权全数转让予接受此权利并签署下列登 记申请表 格（表格丙 ）的 人士。 1. 2. 3. 4. Signature(s)ofShareholder(s)(alljointShareholdersmustsign)股东签署（所有联名股东均须签署） Date: 2017 日期：二 零一七年 月 日 Advaloremstampdutyispayableinconnectionwiththetransferofyourrightstosubscribeforthe RightsShares. 阁下转让供股股份之认购权须缴付从价印花 税。 REGISTRATIONAPPLICATIONFORM 登记申请表格 FormC (Tobecompletedandsignedonlybytheperson(s)towhomtherightstosubscribe fortheRightsShareshavebeentransferred) 表格丙 （仅供已获转让供股股份认购权之人士填写及签署） To: TheDirectors NewRayMedicineInternationalHoldingLimited 致： 新锐医药国际控股有限公司 列位董事 台照 DearSir/Madam, I/WerequestyoutoregisterthenumberofRightsSharesmentionedinBoxBofFormAinmy/ourname(s). I/WeagreetoacceptthesameonthetermsembodiedinthisPALandtheProspectusandsubjecttothe memorandumofassociationandthebye-lawsoftheCompany. 敬启 者： 本人�u吾等谨请阁下将表格甲内乙栏所列之供股股份数目，登记於本人�u吾等名下。本人�u吾等同意按照本 暂定配额通知书及章程所载条 款，以 及在 贵公司之组织章程大纲及公司细则规限 下，接纳此等供股股 份。 ExistingShareholder(s) Pleasemark“X”inthisbox 现有股东请在本栏内填 上「X」号 TobecompletedinBLOCKlettersinENGLISH.Jointapplicantsshouldgivetheaddressof thefirst-namedapplicantonly. 请用英文大楷填 写。联名申请人只须填报排名首位的申请人的地址。 ForChineseapplicant(s),pleaseprovideyourname(s)inbothEnglishandChinese. 中国籍申请人请同时填写中英文姓 名。 NameinEnglish FamilynameorCompanyname Namein 英文姓名 姓氏或公司名称 Chinese Othernames 中文姓名 名字 Name(s)of jointapplicant(s) (ifany) 联名申请人姓名 （如有） AddressinEnglish 英文地址 (Jointapplicants should givetheaddress ofthefirst-named applicantonly) （联名申请人只须 填报排名首位的申请 人的地址） Occupation Tel.no. 职业 电话号码 DividendInstructions股息指示 Nameand Bankaccountnumber银行账户号码 addressofbank 银行名称及地址 1. 2. 3. 4. Signature(s)ofapplicant(s)(alljointapplicant(s)mustsign)申请人签 署（所有联名申请人均须签署） Date: 2017 日期：二 零一七年 月 日 Advaloremstampdutyispayableinconnectionwiththetransferofyourrightstosubscribe fortheRightsShares. 阁下转让供股股份之认购权须缴付从价印花 税。 NewRayMedicineInternationalHoldingLimited 新锐医药国际控股有限公司 (IncorporatedinBermudawithlimitedliability) (StockCode:6108) 10February2017 DearQualifyingShareholder(s), INTRODUCTION Reference is madeto theprospectus ofNew RayMedicineInternational Holding Limited(“Company”) dated10 February2017 inrelationtotheRightsIssue(“Prospectus”).Termsdefinedin theProspectus shallhavethesamemeaningswhenusedhereinunlesscontextotherwiserequires.Inaccordancewiththe termsandconditionsassetoutintheProspectus,theDirectorshaveprovisionallyallottedtoyouanumber ofRightsSharesonthebasisofthree(3)RightsSharesforeveryone(1)Shareinissueregisteredinyour name(s)intheregisterofmembersoftheCompanyontheRecordDate(thatis,Thursday,9February2017) atthesubscriptionpriceofHK$0.275perRightsShare.YourholdingoftheSharesontheRecordDateis setoutinBoxAinFormAandthenumberofRightsSharesprovisionallyallottedtoyouissetoutinBoxB inFormA. AnyRightsSharesprovisionallyallotted,butnotacceptedbytheQualifyingShareholdersorthetransferees ofnil-paidRightsShares,willbeavailableforexcessapplicationsbytheQualifyingShareholdersusingthe ExcessApplicationForm(“EAF”). The Prospectus Documents have not been and will not beregistered under the applicable securities legislation ofany jurisdictions otherthan Hong Kong.Save asdescribedunder theparagraph headed “TheRightsIssue�CRightsofOverseasShareholders”inthesectionheaded“LetterfromtheBoard”inthe Prospectus,noactionhasbeentakenbytheCompanytopermittheofferingoftheRightsIssueinany territoryoutsideHongKong. NopersonsreceivingacopyoftheProspectusoraPALoranEAFinanyjurisdictionoutsideHongKong maytreatitasanofferorinvitationtoapplyfortheRightsShares,unlessintherelevantjurisdiction,such an offeror invitationcouldlawfully bemade withoutcompliancewith anyregistration orother legalor regulatoryrequirements.ItistheresponsibilityofanypersonoutsideHongKongwishingtomakeonhis/ her/its/theirbehalfanapplicationfortheRightsSharesundertheRightsIssuetosatisfyhimself/herself/ itself/themselvesastotheobservanceofthelawsandregulationsofallrelevantjurisdictionincludingthe obtainingofanygovernmentalorotherconsentsandtopayanytaxesanddutiesrequiredtobepaidin suchterritoryorjurisdictioninconnectiontherewith.NoapplicationforRightsShareswillbeacceptedfrom theExcludedShareholders(ifany).TheCompanyreservestherighttorefusetoacceptanyapplicationfor RightsShareswhereitbelievesthatacceptancewouldviolatetheapplicablesecuritiesorotherlawsor regulationsofanyjurisdictionoutsideHongKong. RIGHTSSHARES TheRightsShares,whenallottedandfullypaid,willrankparipassuinallrespectswiththeSharesthenin issue.Holdersoffully-paidRightsShareswillbeentitledtoreceiveallfuturedividendsanddistributions whichmaybedeclared,madeorpaidonorafterthedateofallotmentoftheRightsSharesintheirfully paidform. Subjecttothegrantingofthelistingof,andpermissiontodealin,theRightsSharesinboththeirnil-paid andfully-paidformsontheStockExchangeaswellascompliancewiththestockadmissionrequirements of HKSCC, theRights Shares in both their nil-paid and fully-paid forms will be accepted aseligible securities by HKSCC for deposit,clearance and settlement in CCASS with effect from therespective commencementdatesofdealingsin theRightSharesin boththeirnil-paidand fully-paidformsonthe StockExchangeorsuchotherdatesasmaybedeterminedbyHKSCC.Settlementoftransactionsbetween participantsoftheStockExchangeonanytradingdayisrequiredtotakeplaceinCCASSonthesecond tradingdaythereafter.AllactivitiesunderCCASSaresubjecttotheGeneralRulesofCCASSandCCASS OperationalProceduresineffectfromtimetotime. PROCEDURESFORACCEPTANCE TotakeupyourprovisionalallotmentofRightsSharesinfull,youmustlodgethewholeofthisPALintact withtheRegistrar,TricorInvestorServicesLimitedatLevel22,HopewellCentre,183Queen’sRoadEast, Hong Kong,together witha remittanceforthefullamountpayableonacceptance,asshowninBoxC inFormA,soastobereceivedbynotlaterthan 4:00p.m.onFriday,24February2017(or,underbad weatherconditions,suchlatertimeordateasmentionedintheparagraphheaded“EffectofBadWeather” below).AllremittancesmustbemadeinHongKongdollars.Chequesmustbedrawnonanaccountwith, or cashier’sordersmustbeissuedby,alicensedbankinHongKongandmadepayableto“NEWRAY MEDICINEINTERNATIONALHOLDINGLIMITED―PROVISIONALALLOTMENT”andcrossed“Account PayeeOnly”.SuchpaymentwillconstituteacceptanceoftheprovisionalallotmentofRightsSharesonthe termsofthisPALandtheProspectusandsubjecttothememorandumofassociationandthebye-lawsof theCompany.Noreceiptwillbegivenforsuchremittances.AllenquiriesinconnectionwiththisPALshould beaddressedtotheRegistrarattheaboveaddress. ItshouldbenotedthatunlessthisdulycompletedPAL,togetherwiththeappropriateremittanceshownin BoxCinFormA,hasbeenlodgedinthemannerasdescribedabove,bynotlaterthan4:00p.m.onFriday, 24February2017(or,underbadweatherconditions,suchlatertimeordateasmentionedintheparagraph headed“EffectofBadWeather”below),whetherbytheoriginalallotteeoranypersontowhomtherights havebeenvalidlytransferred,therelevantprovisionalallotmentandallrightsandentitlementsthereunder willbedeemedtohavebeendeclinedandwillbecancelledandsuchRightsShareswillbeavailablefor applicationundertheEAFsbyotherQualifyingShareholders.TheCompanymay(atitssoleandabsolute discretion)treataPALasvalidandbindingontheperson(s)bywhomoronwhosebehalfitislodgedeven ifthePALisnotcompletedinaccordancewiththerelevantinstructions. Completionand returnofthis PALwillconstitute awarrantyand representationtotheCompany, fromsuchperson,thatallregistration,legalandregulatoryrequirementsofallrelevantjurisdictions otherthanHongKong,inconnectionwiththePALandanyacceptanceofit,havebeen,orwillbe, duly compliedwith. The Company reservesthe rightto refuse toaccept any applicationfor the RightsShareswhereitbelievesthatindoingsowouldviolatetheapplicablesecuritieslegislationsor otherlawsorregulationsofanyjurisdiction.Fortheavoidanceofdoubt,neitherHKSCCnorHKSCC NomineesLimitedissubjecttoanyoftheaboverepresentationorwarranty. TRANSFERANDSPLITTING Ifyouwishto transferallofyourrights tosubscribefortheRightsShares provisionallyallotted toyou hereunder,youmustcompleteandsignthe“Formoftransferandnomination”(FormB)andhandthisPAL tothetransferee(s)orthroughwhomyouaretransferringyourrights.Thetransferee(s)mustthencomplete andsignthe“Registrationapplicationform”(FormC)andlodgethisPALintacttogetherwitharemittance forthefullamountpayableonacceptanceassetoutinBoxCinFormAwiththeRegistrar,TricorInvestor ServicesLimitedatLevel22,HopewellCentre,183Queen’sRoadEast,HongKong,soastobereceived bynotlaterthan4:00p.m.onFriday,24February2017(or,underbadweatherconditions,suchlatertime ordateasmentionedintheparagraphheaded“EffectofBadWeather”below).Allremittancesmustbe madeinHongKongdollarsandchequesmustbedrawnonanaccountwith,orcashier’sordersmustbe issuedby,alicensedbankinHongKongandmadepayableto“NEWRAYMEDICINEINTERNATIONAL HOLDING LIMITED―PROVISIONALALLOTMENT” andcrossed“AccountPayee Only”.Itshouldbe notedthatHongKongstampdutyispayableinconnectionwiththetransferofyourrightstosubscribefor therelevantRightsSharestothetransferee(s)andtheacceptancebythetransferee(s)ofsuchrights. Ifyouwishtoacceptonlypartofyourprovisionalallotmentortransferpartofyourrightstosubscribefor theRightsSharesprovisionallyallottedtoyouhereunderortotransferallorpartofyourrightstomorethan oneperson,theoriginalPALmustbesurrenderedandlodgedforcancellationbynotlaterthan4:30p.m. onThursday,16February2017withtheRegistrar,TricorInvestorServicesLimitedatLevel22,Hopewell Centre, 183Queen’sRoadEast,HongKong,who willcancelthisoriginal PALand issuenewPAL(s) in thedenominationsrequiredwhichwillbeavailableforcollectionattheRegistrar,TricorInvestorServices LimitedatLevel22,HopewellCentre,183Queen’sRoadEast,HongKongafter9:00a.m.onthesecond businessdayafterthesurrenderofthisoriginalPAL(s).ItshouldbenotedthatHongKongstampdutyis payableinconnectionwiththetransferofyourrights tosubscribefortherelevantRightsSharestothe transferee(s)and theacceptancebythetransferee(s)ofsuchrights. TheCompanymay(atitssoleand absolutediscretion)treatPAL(s)asvalidandbindingontheperson(s)bywhomoronwhosebehalfitis lodgedevenifthePALisnotcompletedinaccordancewiththerelevantinstructions. TERMINATIONOFTHEUNDERWRITINGAGREEMENT TheUnderwritermayterminatetheUnderwritingAgreementbynoticeinwritingtotheCompanyatanytime priorto4:00p.m.onMonday,27February2017if: (1) inthereasonableopinionoftheUnderwriter,thesuccessoftheRightsIssuewouldbemateriallyand adverselyaffectedby: (a) theintroductionofanynewregulationoranychangeinexistinglaworregulation(orthejudicial interpretationthereof)orotheroccurrenceofanynaturewhatsoeverwhichmayinthereasonable opinionoftheUnderwritermateriallyandadverselyaffectthebusinessorthefinancialortrading positionoftheGroupasawholeorismateriallyadverseinthecontextoftheRightsIssue;or (b) theoccurrenceof anylocal,national orinternational eventor change (whetheror notforming partofa seriesofeventsor changesoccurring,orcontinuingbefore,and/orafterthedateof theUnderwritingAgreement),ofapolitical,military,financial,economicorothernature(whether or not ejusdem generic with any of the forgoing),or in the natureof any local, national or internationaloutbreak orescalationofhostilitiesorarmedconflict,or affectinglocalsecurities marketswhichmay,inthereasonableopinionoftheUnderwriter,materiallyandadverselyaffect thebusinessorthefinancialortradingpositionoftheGroupasawhole;or (c) anymaterialadversechangeafterthesigningoftheUnderwritingAgreementinthebusinessorin thefinancialortradingpositionoftheGroupasawhole;or (d) theimpositionof any moratorium,suspension or materialrestriction ontradingin theShares generallyontheStockExchangeduetoexceptionalfinancialcircumstancesorotherwise;or (e) anysuspensioninthetradingofsecuritiesgenerallyortheSharesontheStockExchangefora periodofmorethan20consecutivebusinessdays,excludinganysuspensioninconnectionwith theclearanceoftheAnnouncementortheProspectus Documentsor otherannouncementsor circularsinconnectionwiththeRightsIssue;or (2) any materialadverse changein market conditions(including,withoutlimitation, a change infiscal ormonetarypolicyorforeign exchangeorcurrencymarkets,suspension orrestrictionoftradingin securitiesandachangeincurrencyconditionsincludesachangeinthesystemunderwhichthevalue oftheHongKongcurrencyispeggedwiththatofthecurrencyoftheUnitedStatesofAmerica)occurs whichinthereasonableopinionoftheUnderwritermakesitinexpedientorinadvisabletoproceedwith theRightsIssue;or (3) theProspectuscontainsinformation(eitherastotheconditionoftheGrouporastoitscompliance withanylawsortheListingRulesoranyapplicableregulations)whichhasnotpriortothedateof theUnderwritingAgreementbeenpubliclyannouncedorpublishedbytheCompanyandwhichmay inthereasonableopinionoftheUnderwriterismaterialtotheGroupasawholeandislikelytoaffect materiallyandadverselythesuccessoftheRightsIssueormightcauseaprudentinvestornottoapply foritsprovisionalallotmentofRightsSharesundertheRightsIssue. TheUnderwritershallbeentitledbynoticeinwritingtotheCompanyservedpriortotheLatestTimefor TerminationtorescindtheUnderwritingAgreementif,priortotheLatestTimeforTermination: (1) any material breach of any of the warranties or undertakings of the Company contained in the UnderwritingAgreementcomestotheknowledgeoftheUnderwriter;or (2) anyeventoccurringormatterarisingonorafterthedateoftheUnderwritingAgreementandpriorto theLatestTimeforTerminationwhichifithadoccurredorarisenbeforethedateoftheUnderwriting Agreementwouldhaverenderedanyoftherepresentations,warrantiesandundertakingsgivenbythe CompanycontainedintheUnderwritingAgreementuntrueorincorrectinanymaterialrespectcomes totheknowledgeoftheUnderwriter. In the event that the Underwriter exercises its rights to terminate or rescind the Underwriting Agreementasdescribedabove,theRightsIssuewillnotproceed. CONDITIONSOFTHERIGHTSISSUE TheRightsIssueisconditionaluponthefollowingconditionsbeingfulfilled: (1) theIncreaseinAuthorisedShareCapitalbecomingeffectivebytheRecordDate; (2) thepassingofan ordinaryresolutionbytheIndependentShareholders attheSGM toapprovethe RightsIssuebynolaterthantheProspectusPostingDate; (3) theStockExchangegrantingoragreeingtogrant(subjecttoallotment)thelistingofandpermission todealinalltheRightsShares(intheirnil-paidandfully-paidforms)bynolaterthantheProspectus PostingDateandtheStockExchangenothavingwithdrawnorrevokedsuchlistingsandpermission onorbeforetheLatestTimeforTermination; (4) thefilingandregistrationofalldocumentsrelatingtotheRightsIssue,whicharerequiredtobefiledor registeredwiththeRegistrarofCompaniesinHongKonginaccordancewiththeCompanies(WUMP) OrdinancebynolaterthantheProspectusPostingDate; (5) thepostingoftheProspectusDocumentstotheQualifyingShareholdersbytheProspectusPosting Date; (6) thecompliancewithandperformanceofalltheundertakingsandobligationsoftheCompanyunder theUnderwritingAgreementbytheLatestTimeforTermination; (7) thedeliverytotheCompanyandtheUnderwriteronorbeforethedateoftheUnderwritingAgreement theOptionHolders’UndertakingsdulyexecutedbyeachholderoftheExercisableShareOptions; (8) compliancewithandperformanceofalltheundertakingsandobligationsofthesignatoryoftheOption Holders’Undertakings;and (9) theUnderwritingAgreementnotbeingterminatedbytheUnderwriterpursuanttothetermsthereofon orbeforetheLatestTimeforTermination. NoneoftheaboveconditionsprecedentiscapableofbeingwaivedbytheUnderwriterandtheCompany otherthanthecondition(6)above.TheUnderwritermaywaivethecondition(6)aboveinwholeorinpartby writtennoticetotheCompany. Iftheaboveconditionsarenotsatisfiedand/orwaivedinwholeorinpartbytherespectivedatesspecified above(orsuchothertimeand/ordatesastheUnderwritermayagreewiththeCompanyinwriting),the UnderwritingAgreementshallterminate(saveinrespectoftheprovisionsinrelationtofeesandexpenses, announcements and confidentiality, indemnity,notices and governinglawand any rights or obligations whichmayaccrueundertheUnderwritingAgreementpriortosuchtermination)andnopartywillhaveany claimagainstanyotherpartyforcost,damages,compensationorotherwise. CHEQUESANDCASHIER’SORDER Allchequesandcashier’sorderswillbepresentedforpaymentimmediatelyuponreceiptandallinterests earnedonsuchmonies(if any)will beretained forthebenefitof theCompany. Completionand return ofthePALwithachequeoracashier’sorderinpaymentfortheRightsShares,whetherbyaQualifying Shareholderoranynominatedtransferee,willconstituteawarrantybytheapplicantthatthechequeorthe cashier’sorderwillbehonouredonfirstpresentation.WithoutprejudicetoitsotherrightsoftheCompany inrespectthereof,theCompanyreservestherighttorejectany PALand/orEAFinrespectofwhichthe accompanyingchequeorcashier’sorderisdishonouredonfirstpresentation,andinthateventtherelevant provisionalallotmentofRightsSharesandallrightsandentitlementsthereunderwillbedeemedtohave beendeclinedandwillbecancelled.YoumustpaytheexactamountpayableuponapplicationforRights Shares,andany underpaidapplicationwillberejected.Intheeventofanoverpaidapplication,arefund cheque,withoutinterest,willbemadeouttoyouonlyif theoverpaidamountis HK$100or above.No receiptwillbeissuedinrespectofanyPALand/orrelevantremittancereceived. SHARECERTIFICATESANDREFUNDCHEQUES SubjecttothefulfilmentoftheconditionsoftheRightsIssue,sharecertificatesforthefully-paidRights Shares areexpectedtobepostedby Monday,6March 2017tothoseShareholdersentitledtheretoby ordinarypostattheirownrisk.You,exceptHKSCCNomineesLimited,willreceiveonesharecertificatefor alltheRightsSharesand/orexcessRightsShares(ifany),bothinfully-paidform,allottedandissuedto you. IftheRightsIssueis terminatedor if yourapplicationforexcessRightsShares isnotsuccessful oris onlypartiallysuccessful,refundcheques,withoutinterest,inrespectoftherelevantportionofapplication moniesreceivedareexpectedtobepostedbyordinarypostatyourownrisktoyourregisteredaddresses onorbeforeMonday,6March2017.Refundcheques(crossed“AccountPayeeOnly”)willbedespatched byordinaryposttotheregisteredaddressesoftherelevantapplicantsoftheRightsSharesattheriskof suchapplicants. EXCESSRIGHTSSHARES Qualifying shareholders may, by way of excess application, applyfor any RightsShares provisionally allotted but not acceptedby the QualifyingShareholders or the transferees of nil-paid RightsShares. ApplicationforexcessRightsSharescanbemadebycompletingtheEAFandlodgingit,togetherwitha separateremittancefortheamountpayableonapplicationinrespectoftheexcessRightsSharesapplied for,inaccordancewiththeinstructionssetoutthereinwiththeRegistrar,TricorInvestorServicesLimitedat Level22,HopewellCentre,183Queen’sRoadEast,HongKong,soastobereceivedbynotlaterthan4:00 p.m.onFriday,24February2017(or,underbadweatherconditions,suchlatertimeordateasmentioned in theparagraphheaded “EffectofBadWeather”below). All remittancesmustbemade bychequeor cashier’sorderinHongKongdollars.Chequesmustbedrawnonanaccountwith,orcashier’sordersmust beissuedby,alicensedbankinHongKongandmadepayableto“NEWRAYMEDICINEINTERNATIONAL HOLDINGLIMITED―EXCESSAPPLICATION”andcrossed“AccountPayeeOnly”.Noreceiptwillbe givenforsuchremittances. The Board willallocatetheexcess RightsShares totheQualifying Shareholderswho have appliedfor excessapplicationona pro-ratabasistotheexcessRightsShares appliedbythem,withoutinvolving allocationofanyfractionalRightsShare.Nopreferencewillbegiventoapplicationsmadefortoppingodd lotholdingstowholeboardlotholdings.ItshouldbenotedthatthelodgingoftheEAFdoesnotassure theQualifyingShareholderofbeingallocatedanyRightsSharesinexcessofthoseofhis/her/itsprovisional allotments. FRACTIONALENTITLEMENTS The Company will not provisionally allot and will not accept applications forany fractions of Rights Shares.AllfractionsofRightsShareswillbeaggregatedandallnil-paidRightsSharesarisingfromsuch aggregationwillbesoldinthemarketifapremium(netofexpenses)canbeachieved,andtheCompany will retain theproceeds from such sales forits own benefit. Detailsof theodd lots arrangement and matchingservicesaresetoutintheProspectus. EFFECTOFBADWEATHER Ifthereisa “black”rainstorm warningora tropicalcyclonewarningsignalnumber8oraboveinforce inHongKongonsuchday(i)atanytimebefore12:00noonandnolongerinforceafter12:00noon,the LatestTimeforAcceptancewillbeextendedto5:00p.m.onthesameBusinessDay;and(ii)atanytime between12:00noonand4:00p.m.,theLatestTimeforAcceptancewillbeextendedtothenextBusiness DaywhichdoesnothaveeitherofthosewarningsinforceinHongKongatanytimebetween9:00a.m.and 4:00p.m.. GENERAL LodgmentofthisPALwith,whererelevant,the“Formoftransferandnomination”(FormB)purportingto havebeensignedbytheperson(s)inwhosefavourthisPALhasbeenissued,shallbeconclusiveevidence ofthetitleorthepartyorpartieslodgingittodealwiththesameandtoreceiveasplitletterofallotment and/orthecertificatesforRightsShares. FurthercopiesoftheProspectusareavailableattheRegistrar,TricorInvestorServicesLimitedatLevel22, HopewellCentre,183Queen’sRoadEast,HongKong. Alldocuments,includingrefundcheques,willbesentbyordinarypostattherisksoftherelevantapplicants or otherpersonsentitledtheretototheirregisteredaddressesby theRegistraronorbeforeMonday,6 March2017.Anyrefundchequeswillbedrawninfavourofthepersonnamedonthisform(orincaseof jointapplicants,thefirst-namedapplicant). This PAL andall acceptances of the offer contained herein shall begovernedby andconstrued in accordancewiththelawsofHongKong. PERSONALDATACOLLECTION―PAL Bycompleting,signingandsubmittingthisPAL,youagreetodisclosetotheCompany,theRegistrarand/or theirrespectiveadvisersandagentspersonaldataandanyinformationwhichtheyrequireaboutyouorthe person(s)forwhosebenefityouhavemadetheacceptanceoftheprovisionalallotmentofRightsShares. ThePersonalData(Privacy)Ordinance (Chapter486oftheLawsofHongKong) providestheholdersof securities with rights to ascertainwhetherthe Companyor theRegistrar holdstheirpersonal data,to obtainacopyofthatdata,andtocorrectanydatathatisinaccurate.InaccordancewiththePersonalData (Privacy)Ordinance(Chapter486oftheLawsofHongKong),theCompanyandtheRegistrarhavetheright tochargeareasonablefeefortheprocessingofanydataaccessrequest.Allrequestsforaccesstodataor correctionofdataorforinformationregardingpoliciesandpracticesandthekindsofdataheldshouldbe addressedtotheCompany,atitsprincipalplaceofbusinessinHongKongatRoom517,5thFloor,Town HealthTechnologyCentre,10-12YuenShunCircuit,SiuLekYuen,Shatin,NewTerritories,HongKongor asnotifiedfromtimetotimeinaccordancewithapplicablelaw,fortheattentionofthecompanysecretary oftheCompany,or(asthecasemaybe)totheRegistraratitsaddresssetoutabovefortheattentionof PrivacyComplianceOfficer. Yoursfaithfully, ByOrderoftheBoard NewRayMedicineInternationalHoldingLimited LeeChikYuet ExecutiveDirector NewRayMedicineInternationalHoldingLimited 新锐医药国际控股有限公司 （於百慕达注册成立之有限公司） （股份代号：6108） 敬启 者： 绪言 兹提述新锐医药国际控股有限公 司（「本公 司」）日 期为二零一七年二月十日有关供股之章程（「章 程」）。除 文义 另有所指外，章程所界定词汇与本暂定配额通知书所采用者具有相同涵 义。根据章程所载条款及条件，董事已 向 阁下暂定配发若干数目供股股份，基准为於记录日期（即二零一七年二月九日（星期 四 ））以 阁下名义在本 公司股东名册上登记之每一(1)股已发行股份可获配发三(3)股供股股份，认购价为每股供股股份0.275港元。阁 下於记录日期持有之股份列於表格甲内甲 栏，而阁下所获暂定配发的供股股份数目则列於表格甲内乙 栏。 任何暂定配发而未获合资格股东或未缴足股款供股股份承让人接纳之供股 股 份，将可供合资格股东使用额外申 请表 格（「额外申请表 格」）作出额外申 请。 章程文件并无亦不会根据香港以外之任何司法权区之适用证券法律登记。除章程「董事会函件」一节中「供股一 海外股东之权利」一 段所述外，本公司概无采取任何行动以批准於香港以外任何地区提呈供 股。 於香港以外任何司法权区并接获章程或暂定配额通知书或额外申请表格之 人 士，不得视之为申请供股股份要约 或邀请，除非有关要约或邀请可於有关司法权区合法地作出而毋须遵照任何登记或其他法律或监管规定则除 外。在香港以外地区而拟为其利益申请供股之供股股份之任何人士，须 自行遵守所有相关司法权区之法例及规 例（包括取得任何政府或其他同意），并缴付有关地区或司法权区就此而规定缴付之任何税项及徵税。本公司将 不会接纳除外股东（如有 ）认 购供股股份的申请。倘本公司相信接纳任何认购供股股份的申请会触犯香港以外 任何司法权区的适用证券或其他法例或规 例，则本公司保留权利拒绝接纳有关申请。 供股股份 供股股份一经配发及缴足，将与当时已发行股份在所有方面享有同等地 位。缴足股款供股股份之持有人将有权 收取於缴足股款供股股份配发日期或以後可能宣派、作出或派付之所有未来股息及分派。 倘未缴股款及缴足股款供股股份获准於联交所上市及买 卖，并符合香港结算之证券收纳规定，未缴股款及缴足 股款供股股份将获香港结算接纳为合资格 证 券，自未缴股款及缴足股款供股股份於联交所之各自开始买卖日期 或於香港结算可能厘定之有关其他日期起，可於中央结算系统内寄存、结算及交收。联交所参与者间之任何交 易必须於其後第二个交易日於中央结算系统交收。於 中央结算系统进行之所有活动均须依据不时有效之中央结 算系统一般规则及中央结算系统运作程序规则进行。 接纳之手续 阁下如欲承购供股股份之全部暂定配额，必须将整份本暂定配额通知书连同表格甲内丙栏所载於接纳时应付 之全数股 款，并且不迟於二零一七年二月二十四日（星期五 ）下午四时正（或於恶劣天气情况下，则於下文「恶 劣天气的影响」一段所述之有关较後时间或日期 ）送交登记处卓佳证券登记有限公司，地址为香港皇后大道东 183号合和中心22楼。所有股款须以港元缴付。支票须以香港之持牌银行户口开出，或银行本票须由香港之持牌 银行发出，及注明抬头人 为「NEWRAYMEDICINEINTERNATIONALHOLDINGLIMITED－PROVISIONAL ALLOTMENT」，并划线注明「只准入抬头人账户」。缴付股款 後，即表示已按本暂定配额通知书及章程所载之 条款，及在本公司组织章程大纲及公司细则的规限下接纳供股股份之暂定配额。本公司将不另发股款收据。所 有有关本暂定配额通知书的查询均须寄交上述地址之登记 处。 务请留意，填妥之本暂定配额通知书连同表格甲内丙栏所示之应缴股款须不迟於二零一七年二月二十四日（星 期五）下午四时正（或於恶劣天气情况下，则於下文「恶劣天气的影响」一段所述之有关较後时间或日期）由原承 配人或任何已有效承让供股权利之人士按上述方式送达登 记 处，否则有关暂定配额及其项下之一切权利及配额 将被视作放弃并予以取消，而有关供股股份将可供其他合资格股东以额外申请表格作出申请。即使暂定配额通 知书并未遵照有关指示填妥，本 公司仍可（全权酌情决 定 ）视 暂定配额通知书为有 效，并使递交暂定配额通知书 的人士或其代表受其约束。 填妥及交回本暂定配额通知书将构成有关人士向本公司作出保证及声 明，其已经或将会就暂定配额通知书及其 任何接纳妥为遵守香港以外所有相关司法权区之一切登 记、法例及法规之规定。倘 本公司相信接纳任何供股股 份申请将违反任何司法权区之适用证券法例或其他法例或法 规，则 本公司保留权利拒绝受理有关申 请。为 免生 疑，香港结算或香港中央结算（代理人）有限公司将概不受任何上述声明或保证规 限。 转让及分拆 阁下如欲转让根据本暂定配额通知书暂定配发予阁下的供股股份的全部认购权，须 填妥及签署「转让及提名 表格」（表格乙 ）并 将本暂定配额通知书交予承让人或接纳阁下转让权利之人士。承让人须填妥及签署「登记 申请 表 格」（表格丙），并将整份本暂定配额通知书连同表格甲内丙栏所载於接纳供股股份时应缴的全数股款， 并且不迟於二零一七年二月二十四日（星期五）下午四时正（或於恶劣天气情况下，则於下文「恶劣天气的影响」 一段所述之有关较後时间或日 期 ）交 回登记处卓佳证券登记有限公司，地址为香港皇后大道东183号合和中心22 楼。所有股款须以港元缴付，而支票须以香港之持牌银行户口开出，或银行本票须由香港之持牌银行发出，及注明抬头人为「NEWRAYMEDICINEINTERNATIONALHOLDINGLIMITED－PROVISIONALALLOTMENT」，并划线注 明「只准入抬头人账户」。谨 请注 意，转让 阁下认购有关供股股份之权利予承让人及承让人接纳该等权利须缴付香港印花 税。 阁下如仅欲接纳阁下的部分暂定配额，或 转让根据本暂定配额通知书暂定配发予 阁下的供股股份的部分认 购权，或 向超过一名人士转让 阁下全部或部分权利，则阁下须不迟於二零一七年二月十六日（星期四）下午 四时三十分前将此份原暂定配额通知书交回登记处卓佳证券登记有限公 司（地址为香港皇后大道东183号合和 中心22楼 ）予以注 销，并 按所需数目发出新暂定配额通知书。新 暂定配额通知书将可於交出此份原暂定配额通 知书後第二个营业日上午九时正後於登记处卓佳证券登记有限公 司（地址为香港皇后大道东183号合和中心22 楼）领取。谨 请注 意，转 让阁下有关供股股份之认购权予承让人及承让人接纳该等权利须缴付香港印花税。即 使暂定配额通知书并未遵照有关指示 填 妥，本 公 司仍 可（全权酌情决定）视 暂 定配额通知书为有效，并 使递交暂 定配额通知书的人士或其代表受其约 束。 终止包销协议 倘出现下述情 况，包 销商可於二零一七年二月二十七 日（星期一 ）下午四时正前随时向本公司发出书面通知以 终止包销协议： (1) 包销商合理认为供股之成功将因以下各项而受到重大不利影响： (a)引入任何新法规或任何现有法例或法规（或其司法诠释）之变动，或发生属任何性质之其他事件，而 包销商可能合理认为对本集团之整体业务或财务或经营状况造成重大不利影 响，或对供股而言属重 大不利；或 (b)发生政治、军 事、财 务、经济或其他性质（不论是否与前述任何一项同类）之任何本地、国 家或国际事 件或变 动（不论是否构成於包销协议日期之前及�u或之後发生或持续之连串事件或变动之一部分 ）， 或性质为任何本地、国 家或国际骚动或敌对行为或武装冲突之 升 级，或 影 响本地证券市场之事件或变 动，而包销商可能合理认为对本集团之整体业务或财务或经营状况造成重大不利影响；或 (c) 於签订包销协议後，本 集团之整体业务或财务或经营状况有任何重大不利变 动；或 (d) 股份在联交所之买卖因特殊金融情况或其他原因而被全面禁 止、暂停或施加重大限制；或 (e) 联交所全面暂停证券买卖或暂停股份买卖，为期超过连续20个营业日（因审批公告或章程文件或与供 股有关之其他公告或通函而暂停者除外 ）；或 (2) 市况出现任何重大不利 变 动（包括但不限於财政或货币政策或外汇或货币市场变 动，或证券买卖被暂停或 受到限制以及货币状况变动，包 括香港货币与美利坚合众国货币汇价挂�h体系之变动 ），而包销商合理认 为将导致进行供股为不宜或不智；或 (3) 章程载有於包销协议日期前并未由本公司宣布或刊发之资料（不论有关本集团之状况或有关本集团遵守任 何法例或上市规则或任何适用法规 ），而 包销商可能合理认为对本集团整体而言乃属重 大，并 可能会对供 股之成功造成重大不利影响，或 导致审慎投资者不申请认购其於供股项下之供股股份暂定配额。 倘於最後终止时限前发生以下事 项，包销商将有权於最後终止时限前向本公司发出书面通知以撤回包销协议： (1) 包销商获悉本公司严重违反任何载於包销协议之保证或承 诺；或 (2) 包销商获悉於包销协议日期或之後但於最後终止时限前出现或发生任何事件或事项，而倘有关事件或事项 於包销协议日期前出现或发 生，将会导致本公司於包销协议项下作出之任何声明、保 证及承诺於任何重大 方面变为失实或不准确。 倘包销商行使其上述权利终止或撤回包销协议，则 供股将不会进行。 供股之条件 供股须待以下条件获达成 後，方可作 实： (1) 增加法定股本於记录日期前生效； (2) 独立股东於不迟於章程寄发日期於股东特别大会上通过普通决议案以批准供股； (3) 联交所於不迟於章程寄发日期批准或同意批准（受配发所规限 ）所有供股股 份（以未缴股款及缴足股款形 式 ）上 市及买卖，且联交所於最後终止时限或之前并无撤销或撤回有关上市及批准； (4) 於不迟於章程寄发日期就根据公 司（清盘及杂项条文 ）条 例须向香港公司注册处处长进行存档或登记之所 有与供股有关之文件进行存档及登记手续； (5) 於章程寄发日期前向合资格股东寄发章程文 件； (6) 於最後终止时限前本公司遵守及履行包销协议项下之所有承诺及责任； (7) 於包销协议日期或之前向本公司及包销商交付各可行使购股权持有人正式签立之购股权持有人承诺； (8) 购股权持有人承诺之签署人遵守及履行所有承诺及责 任；及 (9) 包销商并无於最後终止时限或之前根据包销协议之条款终止包销协议。 除上述第(6)项条件 外，上述先决条件概不可由包销商及本公司豁 免。包销商可向本公司发出书面通知全部或部 分豁免上述第(6)项条件。 倘上述条件未能於上述订明之各日 期（或包销商与本公司可能书面协定之有关其他时间及�u或日期 ）前 获全面 或部分达成及�u或豁 免，则包销协议将告终止（惟涉及费用及开支、公 告及保密 性、弥 偿、通知及规管法律及於 有关终止前根据包销协议可能产生之任何权利或责任之条文除外），且 订 约方将不得就 成 本、损害、赔 偿或其他 费用向任何其他订约方提出申 索。 支票及银行本票 所有支票及银行本票将紧随收取後即时过户，而 自有关款项产生之所有利 息（如有 ）将 拨归本公司所有。填 妥并 交回暂定配额通知书连同支付所申请供股股份股款之支票或银行本 票（不论由合资格股东或任何获提名承让人 交回 ），将 构成申请人之保 证，指支票或银行本票将於首次过户时获兑 现。倘支票或银行本票於首次过户时未能 兑现，在 不影响本公司之其他权利的情况下，本 公司保留拒绝受理任何暂定配额通知书及�u或额外申请表格之 权利，且於该情况下，供股股份之有关暂定配额及其项下之一切权利及配额将视作已遭放弃而被注销。阁下 须於申请供股股份时支付实际应付金 额，任何未缴足股款申请将不获受 理。倘就申请支付过多款 额，则在款额 为100港元或以上时方会向阁下发出不计利息之退款支票。概不会就所接获之任何暂定配额通知书及�u或相 关股款发出收据。 股票及退款支票 待供股条件达成後，所有缴足股款供股股份之股票预期将於二零一七年三月六 日（星期一）或之前以平邮方式 寄发予该等股东，惟 邮误风险概由彼等自行承 担。除 香港中央结算（代理人）有限公司外， 阁下将会就配发及 发行予阁下的所有供股股份及�u或额外供股股份（如有 ）（均为缴足股款）获发一张股票。 倘供股被终止或阁下之额外供股股份申请不成功或仅部分成功，则已收取之有关部分申请股 款（不计利息） 之退款支票预期将於二零一七年三月六日（星期一）或 之前以平邮方式寄发至阁下之登记地址，邮误风险概 由阁下自行承担。退款支票（划线注明「只准入抬头人账户」）将寄发至有关供股股份申请人之登记地址，邮误 风险概由有关申请人自行承担。 额外供股股份 合资格股东可按额外申请之方式申请任何已暂定配发而未获合资格股东或未缴股款供股股份之承让人接纳之 任何供股股 份。提出申请额外供股股份之方法为按照其所载指示填妥额外申请表格，并 於不迟於二零一七年二 月二十四 日（星期五）下午四时正（或於恶劣天气情况 下，则 於下文「恶劣天气的影响」一 段所述之有关较後时 间或日期 ）将表格连同於所申请额外供股股份应缴数额之独立股款一并递交至登记处卓佳证券登记有限公司， 地址为香港皇后大道东183号合和中 心22楼。所有股款须以港元支票或银行本票缴付。支票须以香港之持牌银 行户口开出，或银行本票须由香港之持牌银行发出，及注明抬头人为「NEWRAYMEDICINEINTERNATIONAL HOLDING LIMITED－EXCESS APPLICATION」，并划线注明「只 准入抬头人账户」。本 公司将不另发股款收 据。 董事会将根据已作出额外申请之合资格股东所申请认购之额外供股股份按比例向彼等分配额外供股股 份，当中 不会涉及分配任何零碎供股股份。旨在将碎股补足为完整买卖单位之申请将不会获优先处 理。务 请留意，交回 额外申请表格并不保证合资格股东将获配发超出其暂定配额之任何供股股份。 零碎配额 本公司将不会暂定配发亦不会接受任何供股股份碎股之申请。供股股份之所有碎股将予汇集，倘於扣除开支後 能取得溢价，经汇集所得之所有未缴股款供股股份将於市场出 售，而该等销售所得款项将拨归本公司所有。碎 股安排及对盘服务之详情载於章程内。 恶劣天气的影响 倘於当日「黑色」暴 雨警告或悬挂8号或以上热带气旋警告信号於香港生效，则 ( i )如警告为中午十二时正前任何 时间生效而於中午十二时正後解 除，则最後接纳时限将顺延至同一营业日下午五时正；及 ( i i )如 警告为中午十二 时正至下午四时正内任何时间生 效，最後接纳时限将顺延至下一个於上午九时正至下午四时正期间之任何时间 并无任何该等警告於香港生效之营业 日。 一般事项 本暂定配额通知书连同（如适用 ）宣称由获发本暂定配额通知书人士所签署的「转让及提名表 格」（表格乙 ）一 经交 回，即确证交回的人士有权处理本暂定配额通知书及收取分拆的配额函件及�u或有关供股股份之股 票。 阁下如需要额外的章程，可於登记处卓佳证券登记有限公司索取，地址为香港皇后大道东183号合和中心22楼。 所有文件（包括退款支票 ）将 由登记处於二零一七年三月六 日（星期一）或之前以平邮方式寄至有关申请人或其 他应得人士的登记地址，邮误风险概由收件人承 担。任何退款支票均以本表格上填上之姓名作为抬头人（或如 属联名申请人，则以排名首位的申请人为抬头人）。 本暂定配额通知书及所有接纳其中所载的要约均须受香港法例监管，并 按其诠 释。 收集个人资料－暂定配额通知书 填妥、签署及交回本暂定配额通知书，即表示 阁下同意向本公司、登记处及�u或彼等各自之顾问及代理披露个 人资料及彼等所需有关阁下或阁下为其利益而接纳暂定配发供股股份之人士之任何资料。香 港法例第486 章《个人资料（私隐 ）条 例》赋 予证券持有人权 利，可确定本公司或登记处是否持有其个人资料、索 取有关资料 之副本及更正任何不准确资料。根据香港法例第486章《个人资料（私隐）条例》，本公司及登记处有权就处理任 何查阅资料要求而收取合理费用。有 关查阅资料或更正资料或查阅有关政策及惯例以及持有资料种类之讯息的 所有要求，应寄往本公司香港之主要营业地点香港新界沙田小沥源源顺围10-12号康健科技中心5楼517室或根 据适用法律不时通知之地址，并以本公司之公司秘书为收件人，或（视情况而定 ）寄 往 登记处（於其上述地址 ）， 并以私隐事务主任为收件 人。 此致 列位合资格股东 台照 承董事会命 新锐医药国际控股有限公司 执行董事 李植悦 谨启 二零一七年二月十日